Table 2

Patient characteristics
Patient-level Characteristics Total (N = 3,535) Filgrastim (N = 163) Pegfilgrastim (N = 3,372) P-value
Age, mean (SD) 55.2 (10.8) 57.5 (12.6) 55.1 (10.7) 0.018
Female, n (%) 2,788 (78.9) 119 (73.0) 2,669 (79.2) 0.060
Geographic region, n (%)
 Northeast 248 (7.0) 26 (16.0) 222 (6.6) <0.001
 Midwest 970 (27.4) 38 (23.3) 932 (27.6) 0.227
 South 1,778 (50.3) 79 (48.5) 1,699 (50.4) 0.632
 West 539 (15.3) 20 (12.3) 519 (15.4) 0.279
Tumor type, n (%)
 Breast cancer 2,054(58.1) 84 (51.5) 1,970 (58.4) 0.082
 Colorectal cancer 46 (1.3) 7 (4.3) 39 (1.2) <0.001
 Lung cancer 634 (17.9) 30 (18.4) 604 (17.9) 0.873
 Non-Hodgkin’s lymphoma 594 (16.8) 33 (20.3) 561 (16.6) 0.229
 Ovarian cancer 207 (5.9) 9 (5.5) 198 (5.9) 0.852
Baseline Quan-Charlson comorbidity score, mean (SD)*† 4.5 (2.4) 4.4 (2.5) 4.5 (2.4) 0.520
 Score of 2, n (%) 1,131 (32.0) 57 (35.0) 1,074 (31.9) 0.404
 Score of 3–6, n (%) 1,590 (45.0) 61 (37.4) 1,529 (45.3) 0.047
 Score of ≥ 7, n (%) 805 (22.8) 44 (27.0) 761 (22.6) 0.188
History of anemiaठ3,858 (32.0) 135 (36.2) 3,723 (31.9) 0.078
Count of myelosuppressive chemotherapy agents, mean (SD) for cycles§** 2.13 (0.6) 1.96 (0.6) 2.14 (0.6) <0.001
Use duration, mean (SD)†† - 4.8 (3.3) ‡‡ -
 1 day, % - 19.9 - -
 2 days, % - 9.9 - -
 3 days, % - 14.0 - -
 4–6days, % - 23.9 - -
 ≥ 7 days, % - 32.3 - -

* Baseline is the 1-year period preceding the index date (start of chemotherapy course).

Nine patients (0.3%) had a score of 0 (7 patients) or 1 (2 patients).

Anemia occurring in the 120 days prior to the start of each cycle.

§ Cycle-level data: 12,056 total cycles of which 373 were filgrastim and 11,683 were pegfilgrastim.

** Data by cycle, not by patient, as myelosuppressive characteristics were determined at the cycle level.

†† Calculated from cycles in which filgrastim or pegfilgrastim were found on medical claims. Cycles with pharmacy claims for either were not included, as the precise date for the administration of filgrastim or pegfilgrastim could not be determined. These criteria resulted in 322 filgrastim cycles and 11,510 pegfilgrastim cycles.

‡‡ For pegfilgrastim, there was a mean (SD) of 1.0 (0.15) claims per cycle.

Naeim et al.

Naeim et al. BMC Cancer 2013 13:11   doi:10.1186/1471-2407-13-11

Open Data